// App-Quantinova.ai

: Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program

Researchers

Presenter

  • Amy Paller

Principal Investigators

  • Lawrence F. Eichenfield

  • Michael J Cork

  • Christine Bangert

  • Alan D. Irvine

  • Stephan Weidinger

  • Susan Johnson

  • Irina Lazariciu

  • Herwig Koppensteiner

Medical Centers

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • UC San Diego, Rady Children's Hospital San Diego, San Diego, CA

  • Sheffield Dermatology Research, IICD, University of Sheffield and Sheffield Children’s Hospital, Sheffield, United Kingdom

  • Medical University of Vienna, Vienna, Austria

  • St James Hospital, Trinity College Dublin School of Medicine, Dublin, Ireland

  • University Hospital Schleswig-Holstein, Lubeck, Germany

  • Pfizer Inc., Raleigh-Durham, NC, USA

  • IQVIA, Kirkland, Quebec, Canada

  • Pfizer Corporation Austria GmbH, Vienna, Austria

Locations

  • United States

  • Austria

  • Ireland

  • Canada

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Pulmonary/Respiratory Diseases

  • Oncology (ONC)

  • Dermatology

  • Cardiovascular (CVS)

Disease

  • Pulmonary embolism

  • Atopic Dermatitis

  • Herpes simplex virus infection

  • Shingles

  • Skin carcinoma

  • Solid malignancies

  • Acne

Biomarkers

  • Janus kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT03796676

  • NCT03349060

  • NCT03575871

  • NCT03627767

  • NCT03422822

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved